| Catalog Number |
GPSL |
| Medical Device Problem Code |
Migration or Expulsion of Device (1395)
|
| Health Effect - Clinical Codes |
Erosion (1750); Incontinence (1928); Neurological Deficit/Dysfunction (1982); Pain (1994); Scarring (2061); Blood Loss (2597); Not Applicable (3189)
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
(b)(4).To date the device has not been returned.If the device or further details are received at a later date a supplemental medwatch will be sent.In addition, a review of the batch manufacturing records was conducted and the batch met all finished goods release criteria.E2013037.Reporting period (b)(6) 2018 through (b)(6) 2018.Total number of events ¿ 17.Additional concomitant medical products: artisyn y-shaped mesh - 3; gynecare gynemesh ps - 14.
|
| |
|
Event or Problem Description
|
|
It was reported by an attorney that the patient underwent a gynecological surgical procedure on (b)(6) 2009 and mesh was implanted.It was reported that she experienced pain, erosion of her internal bodily tissue, urinary/bowel problems, bleeding, neuromuscular problems and vaginal scarring.It was reported that the patient has undergone multiple surgeries and revisionary procedures.No additional information was provided.
|
| |
|
Additional Manufacturer Narrative
|
|
Date sent to fda: 04/12/2018 ethicon mdr summary reporting exemption e2013037 reporting period december 1, 2018 through january 31, 2018 supplemental 01 - attachment: [02-28-2018 oto supplemental 01.Xlsx].
|
| |
|
Additional Manufacturer Narrative
|
|
Date sent to fda: 06/23/2018 additional information: d7 h6 patient code: 1928 additional b5 narrative: it was reported that the patient underwent mesh removal on 1/24/2017 due to incontinence.Ethicon mdr summary reporting exemption e2013037 reporting period december 1, 2018 through january 31, 2018 supplemental 02 - attachment: [02-28-2018 oto supplemental 02.Xlsx].
|
| |
|
Additional Manufacturer Narrative
|
|
Date sent to fda: 08/17/2018 ethicon mdr summary reporting exemption e2013037 reporting period december 1, 2018 through january 31, 2018 supplemental 03 - attachment: [02-28-2018 oto supplemental 03.Xlsx].
|
| |
|
Additional Manufacturer Narrative
|
|
Pc-(b)(4).Date sent to fda: (b)(4) 2018.Ethicon mdr summary reporting exemption e2013037
reporting period (b)(4) 2018 through (b)(4) 2018.
|
| |
|
Additional Manufacturer Narrative
|
|
Date sent to fda: 12/27/2018 ethicon mdr summary reporting exemption e2013037 reporting period december 1, 2018 through january 31, 2018 supplemental 05 - attachment: [02-28-2018 oto supplemental 05.Xlsx].
|
| |
|
Additional Manufacturer Narrative
|
|
Date sent to fda: 02/12/2019.Ethicon mdr summary reporting exemption e2013037.Reporting period december 1, 2017 through january 31, 2018.
|
| |
|
Additional Manufacturer Narrative
|
|
Date sent to fda: 4/23/2019.Ethicon mdr summary reporting exemption e2013037.Reporting period december 1, 2018 through january 31, 2018.
|
| |
|
Additional Manufacturer Narrative
|
|
Date sent to the fda: 12/19/2019.Ethicon mdr summary reporting exemption e2013037.Reporting period december 1, 2017 through january 31, 2018.
|
| |
|
Search Alerts/Recalls
|